Hydreight Reports 34% YOY Q1 Rev Growth
Hydreight Reports 34% Year‑Over‑Year Q1 Revenue Growth, Improvement in Bottom‑Line Results, and Delivers Strong Performance Across Verticals
– Vancouver, BC & Las Vegas, NV
Source: Hydreight Technologies Inc.
“It was an outstanding quarter. We exceeded our Q1 projections with approximately 34% YOY growth from our first two verticals, a clear sign that our strategy is working. We also secured new customers for VSDHOne, positioning us strongly to hit our year-end goals… We’re continuing to increase our investments in the first half of 2025 to support this growth and drive sustainable margin improvements.”
— Shane Madden, CEO
Q1 2025 Highlights
- Topline¹ Revenue: C$6.53 million (↑34% YoY)
- GAAP Revenue: C$4.54 million (versus C$3.38 million in Q1 2024)
- Gross Margin: C$1.50 million (up from C$1.23 million in Q1 2024)
- Adjusted EBITDA¹: C$163,000
- GAAP Net Income: C$21,000 (versus net loss of C$309,000 in Q1 2024)
- Cash on hand: C$6.04 million
- Strategic financing (Feb): C$5.4 million gross (C$4.8 million net)
- Nurse sign‑ups: +65% vs Q1 2024
- Pharmacy orders: +48% vs Q1 2024
- Launched Personalized Genetic Testing & Wellness on VSDHOne
Highlights & Subsequent Events
- : Launch of Personalized Genetic Testing & Wellness on VSDHOne
- : Appointed Dr. Roebuck as Director
- : Q4 2024 audited revenue and profitability milestone
- : Presented at Planet MicroCap Showcase & CEM Bermuda
- : Expanded GLP-1 telehealth suite with Liraglutide
- : Partnered with Dr. Franklin Joseph
- : Added oral weight loss therapies
- : Closed C$5.4 million financing
- : Named Top 50 TSXV Company
- : Financing update
- : C$4 million LIFE offering announced
- : Launched NAD+ therapy
- : DRIPBaR Direct launch
- : $10M health accelerator with Victory Square
- : 2024 milestones & 2025 vision update
